Peters, Steven v. Gilead Sciences Inc

CourtCourt of Appeals for the Seventh Circuit
DecidedJuly 14, 2008
Docket06-4290
StatusPublished

This text of Peters, Steven v. Gilead Sciences Inc (Peters, Steven v. Gilead Sciences Inc) is published on Counsel Stack Legal Research, covering Court of Appeals for the Seventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Peters, Steven v. Gilead Sciences Inc, (7th Cir. 2008).

Opinion

In the United States Court of Appeals For the Seventh Circuit ____________

No. 06-4290 STEVEN PETERS, Plaintiff-Appellant, v.

GILEAD SCIENCES, INCORPORATED, Defendant-Appellee. ____________ Appeal from the United States District Court for the Southern District of Indiana, Indianapolis Division. No. 04 C 1338—John Daniel Tinder, Judge. ____________ ARGUED MAY 22, 2007—DECIDED JULY 14, 2008 ____________

Before EASTERBROOK, Chief Judge, and WILLIAMS and SYKES, Circuit Judges. SYKES, Circuit Judge. Steven Peters suffered a shoulder injury while he was employed by Gilead Sciences, Inc. He took a relatively short medical leave to have correc- tive surgery, and when his condition did not improve after returning to work, he took another leave. During his second absence, Gilead filled his position with another employee, and when Peters returned to work, Gilead offered him a different position. He declined and Gilead terminated his employment. 2 No. 06-4290

Peters filed suit against Gilead, alleging (as relevant here) a violation of the Family and Medical Leave Act (“FMLA”), 29 U.S.C. §§ 2601 et seq., and a claim for pro- missory estoppel under Indiana law. Gilead moved for summary judgment on the FMLA claim, arguing that Peters was ineligible for FMLA leave based on a provi- sion in the Act that excludes employees at worksites at which less that 50 employees are employed “if the total number of employees employed by that employer within 75 miles of that worksite is less than 50.” 29 U.S.C. § 2611(2)(B)(ii). It was undisputed that Gilead employed less than 50 employees within 75 miles of Peters’ worksite, making him statutorily ineligible for FMLA leave. It was also undisputed that if Peters was eligible for FMLA leave, Gilead had miscalculated the 12-week duration of his leave and replaced him before it expired. Relying on language in Dormeyer v. Comerica Bank-Illinois, 223 F.3d 579, 582 (7th Cir. 2000), Peters argued that Gilead was equitably estopped from asserting the FMLA’s 50/75 exclusion based on representations made in Gilead’s employee handbook and in letters it sent to Peters regarding his entitlement to 12 weeks of medical leave. The district court concluded Peters had not estab- lished the elements of equitable estoppel and granted summary judgment for Gilead. We reverse. While Dormeyer suggested that FMLA eligibility might, “in an appropriate case,” arise by estoppel, the issue need not have been addressed in this case. Peters alleged a state-law claim for promissory estoppel—an equitable contract remedy that permits enforcement of a promise that induces actual and reason- able reliance on the part of the plaintiff, at least to the extent of the plaintiff’s reliance damages. The doctrine is No. 06-4290 3

available when a promise lacks the elements of contract; a threshold question is whether the promise created an enforceable contract. The medical-leave representations contained in Gilead’s employee handbook (repeated in its letters to Peters) may have created an enforceable contract under Indiana law, giving Peters a contractual right to the equivalent of FMLA leave (that is, 12 weeks) regardless of his statu- tory ineligibility. If the representations in the handbook are not contractually enforceable, Indiana’s promissory- estoppel cause of action allows enforcement of Gilead’s promises to the extent of the reliance harm Peters suf- fered. Accordingly, we need not decide whether this is an “appropriate case” to apply FMLA eligibility-by-estoppel, a possibility assumed but not decided in Dormeyer.

I. Background In July 2001 Peters began employment as a Therapeutic Specialist for Gilead, a pharmaceutical company. As a Therapeutic Specialist, Peters worked from his home in Indianapolis representing and marketing Gilead’s prod- ucts to physicians and healthcare professionals in its Midwest region. In November 2001 Peters suffered a work- related injury to his neck and right shoulder. When he reaggravated his shoulder in October 2002, Peters reported the injury to Gilead and filed a worker’s compensation claim. At the end of November, his physician imposed lifting restrictions, and Peters worked under these restric- tions until early December of that same year. He then underwent corrective surgery, taking what he thought was FMLA medical leave from December 5 through December 16, 2002. 4 No. 06-4290

The day after his leave started, Peters received a letter from Gilead stating in part: The Federal Family and Medical Leave Act (“FMLA”) went into effect August 5, 1993. The act grants eligible employees of covered employers up to twelve weeks of unpaid leave in a twelve month period to care for a newborn or adopted or foster child, to care for the seriously ill parent, child, or spouse of the employee, or to attend to the employee’s own serious health condition. To be eligible for FMLA benefits, an employee must have worked for a cov- ered employer for a total of 12 months and have worked at least 1,250 hours over the previous twelve months. You will retain your employee status during the period of your FMLA Leave. This includes accrual of tenure and vacation, in addition to continued health benefits coverage. You will be guaranteed reinstate- ment in your position, or equivalent position, if you return to work by the time your FMLA leave expires. In this case, since your leave began December 5, 2002, you will need to return to work by February 28, 2003 to be guaranteed such reinstatement. This excerpt (with the exception of the specific start and end dates for the leave) tracks language in Gilead’s em- ployee handbook regarding employees’ entitlement to family and medical leave. The handbook provides, under the bold heading “FAMILY AND MEDICAL CARE LEAVE” and the subheading “ELIGIBILITY”: “A request for family and medical care leave will be granted for all employees employed by the Company [Gilead] for at least twelve months and who have worked 1,250 hours during the twelve months preceding the commencement No. 06-4290 5

of leave.” Like the letter Peters received, the handbook guarantees 12 weeks of family and medical leave during a 12-month period and reinstatement to the same (or an equivalent) position with the company upon return to work. Peters returned to work on December 16, 2002, and worked under restrictions that limited him to left hand and arm work. On March 4, 2003, Peters took a second leave when his doctors began treating him with Neurontin, a drug that causes significant side effects. This second leave lasted until May 5, 2003. At the start of this second leave, Gilead sent Peters a letter, similar to the first, again setting forth his eligibility for medical leave. Dated March 17, 2003, this letter stated: In this case, your original leave began December 5, 2002, and you returned to work as of January 26, 2003 (7 weeks and 4 days). Since you reestablished your leave as of March 4, 2004, you will need to return to work by April 4, 2003 (4 weeks and 3 days) to be guaranteed such reinstatement. The letter erroneously identified January 26 as the date Peters returned from his first leave. In fact, his first leave only lasted until December 16, 2002. Accordingly, the April 4, 2003 return-to-work deadline in the letter was incorrect.1 Properly calculated, Peters’ second leave would have run through May 9, 2003.2 Peters never

1 There is no dispute that the second letter miscalculated Peters’ available leave time. 2 May 9 is the last day of the twelfth workweek of available leave. According to Gilead’s employee handbook, “[e]ligible (continued...) 6 No. 06-4290

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Minard v. ITC Deltacom Communications, Inc.
447 F.3d 352 (Fifth Circuit, 2006)
Jerome Jablon, M.D. v. United States
657 F.2d 1064 (Ninth Circuit, 1981)
Jennifer Dormeyer v. Comerica Bank-Illinois
223 F.3d 579 (Seventh Circuit, 2000)
Rex A. Workman v. United Parcel Service, Inc.
234 F.3d 998 (Seventh Circuit, 2000)
Sam Duty v. Norton-Alcoa Proppants
293 F.3d 481 (Eighth Circuit, 2002)
Rodney Harrell v. United States Postal Service
445 F.3d 913 (Seventh Circuit, 2006)
Brown v. Branch
758 N.E.2d 48 (Indiana Supreme Court, 2001)
Duldulao v. Saint Mary of Nazareth Hospital Center
505 N.E.2d 314 (Illinois Supreme Court, 1987)
Clark v. Millikin Mortgage Co.
495 N.E.2d 544 (Indiana Court of Appeals, 1986)
McCalment v. Eli Lilly & Co.
860 N.E.2d 884 (Indiana Court of Appeals, 2007)
Indiana Heart Associates P.C. v. Bahamonde
714 N.E.2d 309 (Indiana Court of Appeals, 1999)
Die & Mold, Inc. v. Western
448 N.E.2d 44 (Indiana Court of Appeals, 1983)
Damon Corp. v. Estes
750 N.E.2d 891 (Indiana Court of Appeals, 2001)
Jarboe v. Landmark Community Newspapers of Indiana, Inc.
644 N.E.2d 118 (Indiana Supreme Court, 1994)
City of Indianapolis v. Byrns
745 N.E.2d 312 (Indiana Court of Appeals, 2001)
Orr v. Westminster Village North, Inc.
689 N.E.2d 712 (Indiana Supreme Court, 1997)

Cite This Page — Counsel Stack

Bluebook (online)
Peters, Steven v. Gilead Sciences Inc, Counsel Stack Legal Research, https://law.counselstack.com/opinion/peters-steven-v-gilead-sciences-inc-ca7-2008.